DIREKT: DISARMING THE INTRAVASCULAR INNATE IMMUNE RESPONSE TO IMPROVE MODALITIES FOR CHRONIC KIDNEY DISEASE TREATMENT
Grant number: 1074171 | Funding period: 2014 - 2016
Dialysis is the mainstay treatment for patients with end-stage kidney disease while they await transplantation. However, the dialysis process causes inflammation in patients, affecting their health and longevity. This project aims to develop new bioreagents that can be applied to dialysis devices to reduce inflammation and thus improve patient outcomes. These bioreagents will also be used to modify donor kidneys so that they are protected from inflammation associated with transplantation.
Related publications (2)
Enhanced protection of the renal vascular endothelium improves early outcome in kidney transplantation: Preclinical investigations in pig and mouse
Sofia Nordling, Johan Brannstrom, Fredrik Carlsson, Bo Lu, Evelyn Salvaris, Alkwin Wanders, Jos Buijs, Sergio Estrada, Vladimir Tolmachev, Peter J Cowan, Tomas Lorant, Peetra U Magnusson
Ischemia reperfusion injury is one of the major complications responsible for delayed graft function in kidney transplantation. Ap..
Surface modification of pig endothelial cells with a branched heparin conjugate improves their compatibility with human blood
Anjan K Bongoni, Evelyn Salvaris, Sofia Nordling, Nikolai Klymiuk, Eckhard Wolf, David L Ayares, Robert Rieben, Peetra U Magnusson, Peter J Cowan
Corline Heparin Conjugate (CHC), a compound of multiple unfractionated heparin chains, coats cells with a glycocalyx-like layer an..